Key facts
- Rubedo’s last known valuation is $90.0M (Jul 2024).
- It has raised $52.0M; the latest was Later Stage VC ($40.0M) in Oct 2025.
- Notable investors include Alumni Ventures, Khosla Ventures, CDP Venture Capital (Rome), Evolution (Venture Capital), B Heroes — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Rubedo
- ·The full record, as it builds
Funding rounds
No funding rounds for Rubedo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rubedo
Operator of a biopharmaceutical company intended to commercialize novel therapeutics that target and eliminate senescent cells. The company's platform utilizes selective apoptosis of cells in aged or pathological tissues to create tissue regeneration, enabling patients to extend their health span, improve the functions of good cells, and treat age-related diseases.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2018
- Employees
- 35
- Website
- rubedolife.com/
- Ownership
- Privately Held (backing)
Rubedo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rubedo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rubedo in its N-PORT filings yet. We sweep new filings monthly.